Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections
TL;DR: The authors attempt to provide an easy and practical update about the ‘infectious’ safety of TT and examine the management strategies of OIs and other infections more frequently observed in the course of treatment with TT.
Journal ArticleDOI
Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy.
Steven-Huy B. Han,Wuhua Jing,Edward Mena,Michael Li,Brett Pinsky,Hong Tang,Tony Hebden,Timothy Juday +7 more
TL;DR: The current findings clearly indicate the benefits of initiating CHB treatment with an oral antiviral monotherapy recommended as first-line treatment by current guidelines, and are typically not fully eradicated by careful study design.
Journal ArticleDOI
Predictors of HBsAg Seroclearance in HBeAg-Negative Chronic Hepatitis B Patients
Min-Sun Kwak,Eun Ju Cho,Eun-Sun Jang,Jeong Hoon Lee,Su Jong Yu,Yoon Jun Kim,Jung Hwan Yoon,Hyo-Suk Lee +7 more
TL;DR: Old age, sustained inactive phase, and low levels of HBV DNA were independent predictors of HBsAg seroclearance.
Journal ArticleDOI
Association of T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (Tim-3) Polymorphisms with Susceptibility and Disease Progression of HBV Infection
TL;DR: Genetic variants of Tim-3 have an important impact on disease progression of HBV infection and patients infected with HBV could be potential candidates of HCC and HBsAg seroclearance.
Journal ArticleDOI
Seroprevalence of hepatitis B and C viral infections among type 2 diabetics: A cross-sectional study in the Cape Coast metropolis
TL;DR: The seroprevalence of HBV was higher than that of HCV in T2DM patients, which means type 2 diabetes mellitus patients would require necessary preventive measures like prophylaxis, to reduce the risk ofHBV infection and its ramifications.